OS Therapies Inc: A Plain-English Investor Guide

I wrote this guide to help you navigate OS Therapies’ financial filings. My goal is to explain their progress so you can decide if this company fits your investment strategy.

1. What does the company do?

OS Therapies is a "clinical-stage" biotech company. They do not have a product on the market yet. Instead, they focus on research and testing for Osteosarcoma, a rare, aggressive bone cancer in young people.

They have two main technology platforms:

• OST-HER2: Their lead product uses weakened Listeria bacteria to help the immune system attack cancer cells. This aims to prevent bone cancer from returning after surgery.
• OST-tADC: A "plug-and-play" platform that delivers cancer-killing drugs directly into tumors. It uses a smart "linker" that only releases the drug inside the acidic environment of a tumor, which helps protect healthy cells.

2. Major Wins: The Clinical Data

The progress of OST-HER2 is the biggest story this year.

• Trial Success: In their Phase IIb trial, 75% of patients were alive two years after surgery. This compares to 40% in historical groups, a 35% improvement in survival rates.
• Biomarkers: They found blood markers that predict which patients respond best to treatment. This could help doctors personalize care and potentially speed up the approval process.
• Acquisitions: In April 2025, they acquired new intellectual property for $12 million in stock and milestone payments. This expands their pipeline to include potential treatments for lung and prostate cancer.

3. Financial Health: The "Spending" Phase

Because they have no sales, the company is in the "spending" phase. They burn cash to fund research and trials. As of mid-2025, their market value was roughly $49.6 million. In 2024, they lost $8.4 million, mostly due to $6.2 million in research costs. They are not profitable. Their future depends on their $4.2 million in cash reserves and their ability to raise more money from investors.

4. Key Risks

Investing here is high-risk. Here is what could go wrong:

• Regulatory Hurdles: The FDA might demand a massive "Phase III" trial costing $20–$30 million. There is no guarantee their current data will win approval.
• Dilution: Because they have no revenue, they will likely sell more shares to raise money. This creates more shares, which reduces your ownership percentage of the company. They may need to raise $10–$15 million soon.
• Early-Stage Tech: Their second platform, OST-tADC, is still in early testing. It is at least two years away from human trials.

5. Future Outlook

The 2026 roadmap is busy:

• Regulatory Filings: They aim to submit applications for approval in the US, UK, and Europe by late 2026 or early 2027.
• New Studies: They plan to start Phase III studies in late 2026, if they can secure more funding.
• Veterinary Potential: They may license OST-HER2 to treat bone cancer in dogs. This could bring in cash without selling more shares.

Final Thought for Investors: This company is a bet on their science. If the FDA approves their drug, the value could jump significantly. However, because they are currently burning cash and will likely need to raise more capital, you should weigh the potential of their clinical data against the reality that they are still years away from a commercial product.